Lupin receives EIR from USFDA for Mandideep plant

On October 31, the pharmaceutical company Lupin announced that the US health authorities had issued an Establishment Inspection Report (EIR) for its Mandideep Unit-2 manufacturing facility in Madhya Pradesh. When an inspection is satisfactorily concluded, the US Food and Drug Administration (USFDA) awards an EIR to a company.

 

In a regulatory filing, Lupin stated that the EIR was released following the facility's most recent inspection, which took place between August 7 and August 11, 2023. On the BSE, the drug company's shares closed 1.04 percent lower at ₹1128.40 a share.

 

The US FDA gave the pharmaceutical giant permission to sell generic versions of Fluconazole tablets and another medication meant to treat insomnia throughout the day this month. Tablets containing fluconazole are used to treat fungal infections. Fluconazole tablets in strengths of 50 mg, 100 mg, 150 mg, and 200 mg received the USFDA's approval for the abbreviated new drug application, Lupin reported in a regulatory filing.

Top stories
Company

Delta Corp Q1 PAT Declines 68% YoY to Rs 22 crore in FY25

4 mins read . 13 Jul 2024 . 09:30 AM

Company

Zydus Life Gets USFDA Nod for Heart Failure Drug

3 mins read . 13 Jul 2024 . 09:23 AM

Company

RVNL Spurts 10% on Bagging Multiple Orders Worth Rs 390 Cr

4 mins read . 13 Jul 2024 . 09:18 AM

Related Blogs
blog-logo

Share Market

blog-logo

12 mins read . 12 Jul 2024

Ritesh Agarwal: The OYO Founder’s Success Story

  • 0 people read
blog-logo

Share Market

blog-logo

15 mins read . 08 Jul 2024

Best Oil & Gas Stocks in India

  • 0 people read
Kickstart your equities journey today You've got this
By submitting this I agree to the terms & conditions